In our phase 1 trial in 10 patients with mucin 1-positive adenocarcinoma, Cvac was well tolerated, reliably led to T-cell immune responses, and resulted in stable disease in 2 patients, one with renal and the other with ovarian carcinoma [8]. The gene discussed is MUC1; the disease is ovarian carcinoma.